Epstein Joshua D, Knight Tara K, Epstein Joel B, Bride Mark A, Nichol Michael B
Department of Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, California, USA.
Head Neck. 2008 Feb;30(2):178-86. doi: 10.1002/hed.20670.
This study documents the direct medical costs associated with treating oral and pharyngeal squamous cell carcinoma (OSCC) as early- or late-stage disease according to the current standard of care.
This retrospective analysis of California Medicaid claims data calculated direct payments for patients diagnosed with OSCC. Patients were defined as being treated for early- or late-stage disease based on treatment modality. Regression determined significant predictors of year-1 cost of care following diagnosis.
Median year-1 cost of care following initial diagnosis was $25,319 for the 229 patients identified. Regression results determined that treatment modality and medical comorbidities were significant in predicting costs (p < .05). Costs for patients treated as having early-stage OSCC were approximately 36% less than for those treated as having late-stage disease (p = .002).
Treatment for OSCC is a significant cost from Medicaid's perspective, and these data suggest early detection may ease its economic burden.
本研究记录了根据当前护理标准将口腔和咽鳞状细胞癌（OSCC）作为早期或晚期疾病进行治疗所产生的直接医疗费用。
这项对加利福尼亚医疗补助索赔数据的回顾性分析计算了被诊断为OSCC患者的直接支付费用。根据治疗方式将患者定义为接受早期或晚期疾病治疗。回归分析确定了诊断后第一年护理费用的显著预测因素。
在确定的229名患者中，初次诊断后第一年护理费用的中位数为25,319美元。回归结果表明，治疗方式和医疗合并症在预测费用方面具有显著性（p < 0.05）。被视为患有早期OSCC的患者的费用比被视为患有晚期疾病的患者低约36%（p = 0.002）。
从医疗补助的角度来看，OSCC的治疗成本很高，这些数据表明早期检测可能会减轻其经济负担。
